Olpasiran Effectively Reduces Lp(a)-apoB Without Increasing Other apoB Particles: JAMA
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-11-12 03:15 GMT | Update On 2025-11-12 03:42 GMT
Advertisement
Brazil: Researchers have found in a new study that inhibition of apo(a) synthesis with olpasiran significantly lowered Lp(a)-apoB levels without a compensatory rise in non–Lp(a)-apoB, resulting in an overall reduction of total apoB-containing particle concentrations.
The findings, published as a research letter in JAMA Cardiology by Dr. André Zimerman from Hospital Moinhos de Vento, Porto Alegre, Brazil, and colleagues, provide fresh insights into how olpasiran—a small-interfering RNA (siRNA)—influences apolipoprotein B (apoB) particles and their role in
Apolipoprotein B–containing lipoproteins are key contributors to atherosclerosis. Lipoprotein(a), or Lp(a), is a complex molecule comprising an apoB component attached to apolipoprotein(a) [apo(a)]. Earlier studies have shown that olpasiran can reduce Lp(a) levels by more than 95% at higher doses, along with a 15–20% reduction in total apoB concentrations. However, since this effect on apoB was not dose-dependent, researchers aimed to determine how olpasiran affects apoB particles bound to apo(a) (Lp[a]-apoB) versus those not bound (non–Lp[a]-apoB).
The data were derived from the OCEAN(a)-DOSE trial (Olpasiran Trials of Cardiovascular Events and Lipoprotein[a] Reduction), a randomized, double-blind, placebo-controlled, dose-ranging clinical study. The trial enrolled patients with established atherosclerotic cardiovascular disease and elevated Lp(a) concentrations above 150 nmol/L. Changes in apoB levels were analyzed as a prespecified secondary outcome using a linear mixed-effects model.
The study led to the following notable findings:
- The study included 281 participants with a baseline median total apoB concentration of 1306 nmol/L (67 mg/dL).
- Baseline Lp(a)-apoB levels were 260 nmol/L.
- Olpasiran treatment led to a dose-dependent reduction in Lp(a)-apoB levels (P<0.001 for all doses).
- Higher doses of olpasiran achieved more than a 95% decrease in Lp(a)-apoB.
- The absolute reduction in Lp(a)-apoB ranged from 211 to 307 nmol/L.
- A compensatory rise in non–Lp(a)-apoB levels was expected but was minimal, limited to 12% or less across all doses.
- Total apoB concentrations decreased by 16.7% to 18.9% compared with placebo.
- This corresponded to an absolute reduction in apoB levels of 201–228 nmol/L (10–11 mg/dL).
The authors explained that olpasiran likely reduces total apoB by preventing the entry of apoB particles into circulation or enhancing their clearance from the bloodstream. Since Lp(a)-apoB particles have a longer half-life and lower affinity for the LDL receptor than non–Lp(a)-apoB, shifting the balance toward non–Lp(a) particles may promote faster clearance.
The results align with prior findings from studies on pelacarsen, an antisense oligonucleotide targeting apo(a), though olpasiran demonstrated a greater overall reduction in total apoB. This appears to stem from a more pronounced decrease in Lp(a) concentrations, while the effects on non–Lp(a)-apoB were similar for both agents.
"Inhibition of apo(a) synthesis with olpasiran substantially decreased Lp(a)-apoB without triggering a rise in non–Lp(a)-apoB, leading to an overall decline in total apoB-containing lipoproteins. These results reinforce olpasiran’s potential as a promising therapy to reduce atherogenic particle burden and cardiovascular risk," the authors concluded.
Reference:
Zimerman A, López JAG, Rosenson RS, et al. Small-Interfering RNA Olpasiran and Apolipoprotein B Particles. JAMA Cardiol. Published online November 05, 2025. doi:10.1001/jamacardio.2025.4105
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.